Information on the Department's spend on breast and prostate cancer awareness activity in each year since 2005 has been presented in the following table:

£

Breast

Prostate

2005-06

27,236

89,400

2006-07

54,504

206,952

2007-08

87,578

126,000

2008-09

21,702

135,000

2009-10

30,715

437,000

2010-11

3,778,791

276,500

2011-12

921,431

102,000

Notes: 1. Figures have been rounded to the nearest pound. 2. 2005 figures for breast cancer do not include storage and distribution costs of breast cancer awareness literature as these were unavailable for this year. 3. In 2009-10 £86,000 (of the £437,000) in funding for prostate cancer awareness also funded activity for bowel and lung cancer. 4. In 2010-11 £7,500 (of the £276,500) in funding for prostate cancer awareness also funded activity for bowel and lung cancer. 5. In 2010-11 £3,745,000 (of the £3,778,791) in funding for breast cancer awareness activity also funded activity for either bowel cancer, lung cancer or both. 6. The 2011-12 spend for prostate cancer is forecasted end of year expenditure.

Figures for the Department's total expenditure on research on breast and prostate cancers in each year since 2005 are not available. Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the Department's total health research expenditure was devolved to and managed by national health service organisations. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. The organisations have accounted for their use of the allocations they have received from the Department in an annual research and development report. The reports identify total, aggregated expenditure on national priority areas, including cancer. They do not provide details of research into particular cancer sites.

The NIHR Clinical Research Network (CRN) is currently hosting 103 studies in breast cancer, and 37 in prostate cancer, that are in set-up or recruiting patients. Expenditure by the CRN on research into particular cancer sites cannot be disaggregated from total CRN expenditure.